Literature DB >> 30713594

TIL therapy and anti-CTLA4: can they co-exist?

Marie-Andrée Forget1,2, Cara Haymaker1,2, Rodabe N Amaria1,2, Chantale Bernatchez1,2.   

Abstract

Entities:  

Keywords:  CTLA4; TIL; metastatic melanoma

Year:  2019        PMID： 30713594      PMCID： PMC6343756          DOI： 10.18632/oncotarget.26509

Source DB:  PubMed          Journal:  Oncotarget        ISSN： 1949-2553


× No keyword cloud information.
  8 in total

1.  Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy.

Authors:  Steven A Rosenberg; James C Yang; Richard M Sherry; Udai S Kammula; Marybeth S Hughes; Giao Q Phan; Deborah E Citrin; Nicholas P Restifo; Paul F Robbins; John R Wunderlich; Kathleen E Morton; Carolyn M Laurencot; Seth M Steinberg; Donald E White; Mark E Dudley
Journal:  Clin Cancer Res       Date:  2011-04-15       Impact factor: 12.531

2.  Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome.

Authors:  Marie-Andrée Forget; Cara Haymaker; Kenneth R Hess; Yuzhong Jeff Meng; Caitlin Creasy; Tatiana Karpinets; Orenthial J Fulbright; Jason Roszik; Scott E Woodman; Young Uk Kim; Donastas Sakellariou-Thompson; Ankit Bhatta; Arely Wahl; Esteban Flores; Shawne T Thorsen; René J Tavera; Renjith Ramachandran; Audrey M Gonzalez; Christopher L Toth; Seth Wardell; Rahmatu Mansaray; Vruti Patel; Destiny Joy Carpio; Carol Vaughn; Chantell M Farinas; Portia G Velasquez; Wen-Jen Hwu; Sapna P Patel; Michael A Davies; Adi Diab; Isabella C Glitza; Hussein Tawbi; Michael K Wong; Suzanne Cain; Merrick I Ross; Jeffrey E Lee; Jeffrey E Gershenwald; Anthony Lucci; Richard Royal; Janice N Cormier; Jennifer A Wargo; Laszlo G Radvanyi; Carlos A Torres-Cabala; Rameen Beroukhim; Patrick Hwu; Rodabe N Amaria; Chantale Bernatchez
Journal:  Clin Cancer Res       Date:  2018-05-30       Impact factor: 12.531

3.  Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients.

Authors:  Laszlo G Radvanyi; Chantale Bernatchez; Minying Zhang; Patricia S Fox; Priscilla Miller; Jessica Chacon; Richard Wu; Gregory Lizee; Sandy Mahoney; Gladys Alvarado; Michelle Glass; Valen E Johnson; John D McMannis; Elizabeth Shpall; Victor Prieto; Nicholas Papadopoulos; Kevin Kim; Jade Homsi; Agop Bedikian; Wen-Jen Hwu; Sapna Patel; Merrick I Ross; Jeffrey E Lee; Jeffrey E Gershenwald; Anthony Lucci; Richard Royal; Janice N Cormier; Michael A Davies; Rahmatu Mansaray; Orenthial J Fulbright; Christopher Toth; Renjith Ramachandran; Seth Wardell; Audrey Gonzalez; Patrick Hwu
Journal:  Clin Cancer Res       Date:  2012-10-02       Impact factor: 12.531

4.  Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma.

Authors:  Shari Pilon-Thomas; Lisa Kuhn; Sabine Ellwanger; William Janssen; Erica Royster; Suroosh Marzban; Ragini Kudchadkar; Jonathan Zager; Geoffrey Gibney; Vernon K Sondak; Jeffrey Weber; James J Mulé; Amod A Sarnaik
Journal:  J Immunother       Date:  2012-10       Impact factor: 4.456

5.  Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies.

Authors:  Michal J Besser; Ronnie Shapira-Frommer; Orit Itzhaki; Avraham J Treves; Douglas B Zippel; Daphna Levy; Adva Kubi; Noa Shoshani; Dragoslav Zikich; Yaara Ohayon; Daniel Ohayon; Bruria Shalmon; Gal Markel; Ronit Yerushalmi; Sara Apter; Alon Ben-Nun; Eytan Ben-Ami; Avichai Shimoni; Arnon Nagler; Jacob Schachter
Journal:  Clin Cancer Res       Date:  2013-05-20       Impact factor: 12.531

6.  Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen.

Authors:  Rikke Andersen; Marco Donia; Eva Ellebaek; Troels Holz Borch; Per Kongsted; Trine Zeeberg Iversen; Lisbet Rosenkrantz Hölmich; Helle Westergren Hendel; Özcan Met; Mads Hald Andersen; Per Thor Straten; Inge Marie Svane
Journal:  Clin Cancer Res       Date:  2016-03-22       Impact factor: 12.531

7.  Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.

Authors:  Frank Stephen Hodi; Vanna Chiarion-Sileni; Rene Gonzalez; Jean-Jacques Grob; Piotr Rutkowski; Charles Lance Cowey; Christopher D Lao; Dirk Schadendorf; John Wagstaff; Reinhard Dummer; Pier Francesco Ferrucci; Michael Smylie; Andrew Hill; David Hogg; Ivan Marquez-Rodas; Joel Jiang; Jasmine Rizzo; James Larkin; Jedd D Wolchok
Journal:  Lancet Oncol       Date:  2018-10-22       Impact factor: 41.316

8.  Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma.

Authors:  Jon Bjoern; Rikke Lyngaa; Rikke Andersen; Lisbet Rosenkrantz Hölmich; Sine Reker Hadrup; Marco Donia; Inge Marie Svane
Journal:  Oncotarget       Date:  2017-04-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.